Abstract
International air travel has been recognized as a crucial factor in the cross-regional transmission of monkeypox (now known as mpox) since this disease rapidly spread across the globe in May 2022. On September 6, 2022, Hong Kong SAR (HK) reported its first imported mpox case with travel history of the United States (US), Canada, and the Philippines. In this study, we estimated the importation risk to HK from 25 international departures from May 1 to September 6, 2022, based on the prevalence of pre-symptomatic mpox cases in the study regions, and time-varying flight mobility evaluated by aggregating multiple open-access air travel datasets (e.g., OpenSky, Aviation Edge). The result indicated that the US had the most significant importation risk of 0.63 (95% CI: 0.32, 0.95) during the study period, followed by the United Kingdom (UK) and Canada with a risk of 0.29 (95% CI: 0.10, 0.63) and 0.17 (95% CI: 0.08, 0.32), respectively. Our study demonstrated that the importation risk of mpox from the US and Canada was substantially higher than other regions, which was aligned with the travel history of the first reported case in HK. Our study provided a simplified computational method for estimating the importation risk of mpox virus based on air travel mobility and disease prevalence. Estimating the international importation risk of mpox is essential for appropriately designing and timely adjusting emergency public health strategies and inbound measures.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
the Key Program for International Science and Technology Cooperation Projects of China [grant no. 2022YFE0112300], National Natural Science Foundation of China [grant nos. 61976181, 62261136549, U22B2036], Key Technology Research and Development Program of Science and Technology - Scientific and Technological Innovation Team of Shaanxi Province [grant no. 2020TD-013].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data underlying this article and these programs will be shared on reasonable request with the corresponding author (email to the corresponding author). The database of the air travel and mpox cases is publicly available at Crowdsourced air traffic data from The OpenSky Network 2020 | Zenodo, Aviation Edge - Database and API - Aviation database and API (aviation-edge.com), Mpox (monkeypox) - Our World in Data, respectively.
